Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study
| Autor: | Stintzing, S., Miller-Phillips, L., Modest, D.P., Fischer von Weikersthal, L., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Kahl, C., Seipelt, G., Kullmann, F., Stauch, M., Scheithauer, W., Held, S., Moehler, M., Jagenburg, A., Kirchner, T., Jung, A., Heinemann, V. |
|---|---|
| Zdroj: | In European Journal of Cancer July 2017 79:50-60 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect